Search

Your search keyword '"Lotan, Yair"' showing total 2,559 results
Start Over Author "Lotan, Yair" Publication Type Academic Journals
2,559 results on '"Lotan, Yair"'

1. Mitochondrial complex I promotes kidney cancer metastasis

Author

Bezwada, Divya, Perelli, Luigi, Lesner, Nicholas P., Cai, Ling, Brooks, Bailey, Wu, Zheng, Vu, Hieu S., Sondhi, Varun, Cassidy, Daniel L., Kasitinon, Stacy, Kelekar, Sherwin, Cai, Feng, Aurora, Arin B., Patrick, McKenzie, Leach, Ashley, Ghandour, Rashed, Zhang, Yuanyuan, Do, Duyen, McDaniel, Phyllis, Sudderth, Jessica, Dumesnil, Dennis, House, Sara, Rosales, Tracy, Poole, Alan M., Lotan, Yair, Woldu, Solomon, Bagrodia, Aditya, Meng, Xiaosong, Cadeddu, Jeffrey A., Mishra, Prashant, Garcia-Bermudez, Javier, Pedrosa, Ivan, Kapur, Payal, Courtney, Kevin D., Malloy, Craig R., Genovese, Giannicola, Margulis, Vitaly, and DeBerardinis, Ralph J.

Published
2024
Full Text
View/download PDF

2. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.

Author

Gore, John, Wolff, Erika, Comstock, Bryan, Follmer, Kristin, Nash, Michael, Basu, Anirban, Chisolm, Stephanie, MacLean, Douglas, Lee, Jenney, Lotan, Yair, Porten, Sima, Steinberg, Gary, Chang, Sam, Gilbert, Scott, Kessler, Larry, and Smith, Angela

Subjects
Administration,  intravesical, Non-muscle invasive bladder cancer, Observational study, Patient-centered care, Pragmatic trial, Quality of life, Radical cystectomy, Humans, Adjuvants, Immunologic, Administration, Intravesical, BCG Vaccine, Cystectomy, Multicenter Studies as Topic, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Non-Muscle Invasive Bladder Neoplasms, Observational Studies as Topic, Prospective Studies, Quality of Life, Urinary Bladder Neoplasms, Pragmatic Clinical Trials as Topic
Abstract

BACKGROUND: Bladder cancer poses a significant public health burden, with high recurrence and progression rates in patients with non-muscle-invasive bladder cancer (NMIBC). Current treatment options include bladder-sparing therapies (BST) and radical cystectomy, both with associated risks and benefits. However, evidence supporting optimal management decisions for patients with recurrent high-grade NMIBC remains limited, leading to uncertainty for patients and clinicians. The CISTO (Comparison of Intravesical Therapy and Surgery as Treatment Options) Study aims to address this critical knowledge gap by comparing outcomes between patients undergoing BST and radical cystectomy. METHODS: The CISTO Study is a pragmatic, prospective observational cohort trial across 36 academic and community urology practices in the US. The study will enroll 572 patients with a diagnosis of recurrent high-grade NMIBC who select management with either BST or radical cystectomy. The primary outcome is health-related quality of life (QOL) at 12 months as measured with the EORTC-QLQ-C30. Secondary outcomes include bladder cancer-specific QOL, progression-free survival, cancer-specific survival, and financial toxicity. The study will also assess patient preferences for treatment outcomes. Statistical analyses will employ targeted maximum likelihood estimation (TMLE) to address treatment selection bias and confounding by indication. DISCUSSION: The CISTO Study is powered to detect clinically important differences in QOL and cancer-specific survival between the two treatment approaches. By including a diverse patient population, the study also aims to assess outcomes across the following patient characteristics: age, gender, race, burden of comorbid health conditions, cancer severity, caregiver status, social determinants of health, and rurality. Treatment outcomes may also vary by patient preferences, health literacy, and baseline QOL. The CISTO Study will fill a crucial evidence gap in the management of recurrent high-grade NMIBC, providing evidence-based guidance for patients and clinicians in choosing between BST and radical cystectomy. The CISTO study will provide an evidence-based approach to identifying the right treatment for the right patient at the right time in the challenging clinical setting of recurrent high-grade NMIBC. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03933826. Registered on May 1, 2019.

Published
2023

5. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer

Author

Amara, Chandra Sekhar, Kami Reddy, Karthik Reddy, Yuntao, Yang, Chan, Yuen San, Piyarathna, Danthasinghe Waduge Badrajee, Dobrolecki, Lacey Elizabeth, Shih, David J. H., Shi, Zhongcheng, Xu, Jun, Huang, Shixia, Ellis, Matthew J., Apolo, Andrea B., Ballester, Leomar Y., Gao, Jianjun, Hansel, Donna E., Lotan, Yair, Hodges, H. Courtney, Lerner, Seth P., Creighton, Chad J., Sreekumar, Arun, Zheng, W. Jim, Msaouel, Pavlos, Kavuri, Shyam M., and Putluri, Nagireddy

Published
2024
Full Text
View/download PDF

6. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.

Author

Chou, Jonathan, Trepka, Kai, Sjöström, Martin, Egusa, Emily, Chu, Carissa, Zhu, Jun, Chan, Emily, Gibb, Ewan, Badura, Michelle, Contreras-Sanz, Alberto, Stohr, Bradley, Meng, Maxwell, Pruthi, Raj, Lotan, Yair, Black, Peter, Porten, Sima, Koshkin, Vadim, Friedlander, Terence, and Feng, Felix

Subjects
Antibody-drug conjugate, Bladder cancer, Enfortumab vedotin, Molecular subtypes, Sacituzumab govitecan, Urothelial cancer, Humans, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Immunoconjugates, Cell Adhesion Molecules, RNA, Messenger
Abstract

Sacituzumab govitecan (SG) is an antibody-drug conjugate (ADC) targeting TROP2, which has recently been approved for treatment-refractory metastatic urothelial cancer (UC). However, the variability of TROP2 expression across different bladder cancer (BC) subtypes, as well as after enfortumab vedotin (EV) exposure, remains unknown. Using gene expression data from four clinical cohorts with >1400 patient samples of muscle-invasive BC and a BC tissue microarray, we found that TROP2 mRNA and protein are highly expressed across basal, luminal, and stroma-rich subtypes, but depleted in the neuroendocrine subtype. In addition, TROP2 mRNA levels are correlated with NECTIN4 mRNA but are more highly expressed than NECTIN4 mRNA in patient cohorts and BC cell lines. Moreover, CRISPR/Cas9-mediated knockdown of TROP2 demonstrates that its expression is one factor governing SG sensitivity. After prolonged EV exposure, cells can downregulate NECTIN4, leading to EV resistance, but retain TROP2 expression and remain sensitive to SG, suggesting nonoverlapping resistance mechanisms to these ADCs. While our findings warrant further validation, they have significant implications for biomarker development, patient selection, and treatment sequencing in the clinic as well as clinical trial design and stratification for metastatic BC patients. PATIENT SUMMARY: In this report, we investigated the expression levels of the drug target TROP2 across different molecular subtypes of bladder cancer in multiple patient cohorts and cell lines. We found high levels of TROP2 in most subtypes except in the neuroendocrine subtype. Overall, TROP2 gene expression is higher than NECTIN4 gene expression, and cells resistant to enfortumab vedotin (EV), a NECTIN4-targeting antibody-drug conjugate, remain sensitive to sacituzumab govitecan (SG). Our findings suggest that SG may be effective across most bladder cancer subtypes, including the bladder cancers previously treated with EV.

Published
2022

8. Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN)

Author

Gunenc, Damla, Issa, Wadih, Gerald, Thomas, Zhou, Qinhan, Zhang, Song, Ibezue, I. Chidera, Bhanvadia, Raj, Tachibana, Isamu, Brugarolas, James, Hammers, Hans, Qin, Qian, Kapur, Payal, Woldu, Solomon, Gaston, Kris, Lotan, Yair, Cadeddu, Jeffrey, Wang, Andrew Z., Margulis, Vitaly, and Zhang, Tian

Published
2024
Full Text
View/download PDF

13. Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma

Author

von Deimling, Markus, D’Andrea, David, Pradere, Benjamin, Laukhtina, Ekaterina, Yanagisawa, Takafumi, Kawada, Tatsushi, Majdoub, Muhammad, Rajwa, Pawel, Pallauf, Maximilian, Singla, Nirmish, Soria, Francesco, Margulis, Vitaly, Chlosta, Piotr, Karakiewicz, Pierre I., Roupret, Morgan, Teoh, Jeremy Yuen-Chun, Fisch, Margit, Rink, Michael, Moschini, Marco, Lotan, Yair, and Shariat, Shahrokh F.

Published
2023
Full Text
View/download PDF

14. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Author

Chu, Carissa E, Sjöström, Martin, Egusa, Emily A, Gibb, Ewan A, Badura, Michelle L, Zhu, Jun, Koshkin, Vadim S, Stohr, Bradley A, Meng, Maxwell V, Pruthi, Raj S, Friedlander, Terence W, Lotan, Yair, Black, Peter C, Porten, Sima P, Feng, Felix Y, and Chou, Jonathan

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Biotechnology, Urologic Diseases, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Antibodies, Monoclonal, Carcinoma, Transitional Cell, Cell Adhesion Molecules, Female, Gene Expression Regulation, Neoplastic, Humans, Immunoconjugates, Tumor Cells, Cultured, Urinary Bladder Neoplasms, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeEnfortumab vedotin (EV) is an antibody-drug conjugate (ADC) targeting NECTIN4 (encoded by the PVRL4/NECTIN4 gene) approved for treatment-refractory metastatic urothelial cancer. Factors that mediate sensitivity or resistance to EV are unknown. In this study, we sought to (i) examine heterogeneity of NECTIN4 gene expression across molecular subtypes of bladder cancer and (ii) determine whether NECTIN4 expression mediates EV sensitivity or resistance.Experimental designMolecular subtyping and NECTIN4 expression data from seven muscle-invasive bladder cancer clinical cohorts (n = 1,915 total specimens) were used to assess NECTIN4 expression across molecular subtypes. The outcome of the transcriptomic analysis was relative NECTIN4 expression in the consensus molecular subtypes of bladder cancer. Expression of NECTIN4 was validated in bladder cancer cell lines. NECTIN4 was stably overexpressed or knocked down in basal and luminal bladder cancer cell lines and EV drug sensitivity assays were performed, as measured by cell proliferation and clonogenic assays.ResultsNECTIN4 expression is heterogenous across molecular subtypes of bladder cancer and significantly enriched in luminal subtypes. NECTIN4 expression is positively correlated with luminal markers GATA3, FOXA1, and PPARG across all cohorts. NECTIN4 expression is both necessary and sufficient for EV sensitivity in luminal and basal subtypes of urothelial bladder cancer cells. Downregulation of NECTIN4 leads to EV resistance.ConclusionsSensitivity to EV is mediated by expression of NECTIN4, which is enriched in luminal subtypes of bladder cancer. These findings may have implications for biomarker development, patient selection, and the inclusion of molecular subtyping in ongoing and future EV clinical trials.See related commentary by Teo and Rosenberg, p. 4950.

Published
2021

15. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.

Author

DAndrea, David, Matin, Surena, Black, Peter, Petros, Firas, Zargar, Homayoun, Dinney, Colin, Cookson, Michael, Kassouf, Wassim, DallEra, Marc, McGrath, John, Wright, Jonathan, Thorpe, Andrew, Morgan, Todd, Holzbeierlein, Jeffrey, Bivalacqua, Trinity, Sridhar, Srikala, North, Scott, Barocas, Daniel, Lotan, Yair, Stephenson, Andrew, van Rhijn, Bas, Spiess, Philippe, Daneshmand, Siamak, and Shariat, Shahrokh

Subjects
#BladderCancer, #blcsm, #uroonc, #utuc, bladder cancer, neoadjuvant chemotherapy, response, survival, upper tract urothelial carcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Cisplatin, Comparative Effectiveness Research, Cystectomy, Deoxycytidine, Doxorubicin, Female, Humans, Kidney Neoplasms, Male, Methotrexate, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Nephroureterectomy, Proportional Hazards Models, Retrospective Studies, Survival Rate, Treatment Outcome, Ureteral Neoplasms, Urinary Bladder Neoplasms, Vinblastine, Gemcitabine
Abstract

OBJECTIVE: To assess the differential response to neoadjuvant chemotherapy (NAC) in patients with urothelial carcinoma of the bladder (UCB) compared to upper tract urothelial carcioma (UTUC) treated with radical surgery. PATIENTS AND METHODS: Data from 1299 patients with UCB and 276 with UTUC were obtained from multicentric collaborations. The association of disease location (UCB vs UTUC) with pathological complete response (pCR, defined as a post-treatment pathological stage ypT0N0) and pathological objective response (pOR, defined as ypT0-Ta-Tis-T1N0) after NAC was evaluated using logistic regression analyses. The association with overall (OS) and cancer-specific survival (CSS) was evaluated using Cox regression analyses. RESULTS: A pCR was found in 250 (19.2%) patients with UCB and in 23 (8.3%) with UTUC (P

Published
2021

21. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis

Author

de Jong, Joep J, Liu, Yang, Robertson, A Gordon, Seiler, Roland, Groeneveld, Clarice S, van der Heijden, Michiel S, Wright, Jonathan L, Douglas, James, Dall’Era, Marc, Crabb, Simon J, van Rhijn, Bas WG, van Kessel, Kim EM, Davicioni, Elai, Castro, Mauro AA, Lotan, Yair, Zwarthoff, Ellen C, Black, Peter C, Boormans, Joost L, and Gibb, Ewan A

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Biotechnology, Cancer, Human Genome, Urologic Diseases, Genetics, Good Health and Well Being, Aged, Biomarkers, Tumor, Carcinoma, Papillary, Combined Modality Therapy, Cystectomy, Female, Follow-Up Studies, Gene Expression Profiling, Genetic Predisposition to Disease, Humans, Male, Middle Aged, Muscle Neoplasms, Neoadjuvant Therapy, Prognosis, RNA, Long Noncoding, Retrospective Studies, Survival Rate, Urinary Bladder Neoplasms, Gene expression analysis, Long non-coding RNA, Molecular subtypes, Muscle-invasive bladder cancer, Clinical Sciences
Abstract

BACKGROUND:Muscle-invasive bladder cancer (MIBC) is a heterogeneous disease, and gene expression profiling has identified several molecular subtypes with distinct biological and clinicopathological characteristics. While MIBC subtyping has primarily been based on messenger RNA (mRNA), long non-coding RNAs (lncRNAs) may provide additional resolution. METHODS:LncRNA expression was quantified from microarray data of a MIBC cohort treated with neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) (n = 223). Unsupervised consensus clustering of highly variant lncRNAs identified a four-cluster solution, which was characterized using a panel of MIBC biomarkers, regulon activity profiles, gene signatures, and survival analysis. The four-cluster solution was confirmed in The Cancer Genome Atlas (TCGA) cohort (n = 405). A single-sample genomic classifier (GC) was trained using ridge-penalized logistic regression and validated in two independent cohorts (n = 255 and n = 94). RESULTS:NAC and TCGA cohorts both contained an lncRNA cluster (LC3) with favorable prognosis that was enriched with tumors of the luminal-papillary (LP) subtype. In both cohorts, patients with LP tumors in LC3 (LPL-C3) were younger and had organ-confined, node-negative disease. The LPL-C3 tumors had enhanced FGFR3, SHH, and wild-type p53 pathway activity. In the TCGA cohort, LPL-C3 tumors were enriched for FGFR3 mutations and depleted for TP53 and RB1 mutations. A GC trained to identify these LPL-C3 patients showed robust performance in two validation cohorts. CONCLUSIONS:Using lncRNA expression profiles, we identified a biologically distinct subgroup of luminal-papillary MIBC with a favorable prognosis. These data suggest that lncRNAs provide additional information for higher-resolution subtyping, potentially improving precision patient management.

Published
2019

22. Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer

Author

von Deimling, Markus, Mertens, Laura S., van Rhijn, Bas W.G., Lotan, Yair, Spiess, Philippe E., Daneshmand, Siamak, Black, Peter C., Pallauf, Maximilian, D'Andrea, David, Moschini, Marco, Soria, Francesco, Del Giudice, Francesco, Afferi, Luca, Laukhtina, Ekaterina, Yanagisawa, Takafumi, Kawada, Tatsushi, Teoh, Jeremy Y.-C., Abufaraj, Mohammad, Ploussard, Guillaume, Roumiguié, Mathieu, Karakiewicz, Pierre I., Babjuk, Marko, Gontero, Paolo, Xylinas, Evanguelos, Rink, Michael, Shariat, Shahrokh F., and Pradere, Benjamin

Published
2023
Full Text
View/download PDF

25. Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer

Author

Einerhand, Sarah M. H., Black, Anna J., Zargar, Homayoun, Fairey, Adrian S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobson, Niels-Erik, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Kassouf, Wassim, Dall’Era, Marc A., Sridhar, Srikala S., McGrath, Jonathan S., Aning, Jonathan, Shariat, Shahrokh F., Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Grivas, Petros, Garcia, Jorge A., Stephenson, Andrew J., Shah, Jay B., Daneshmand, Siamak, Zargar-Shoshtari, Kamran, Spiess, Philippe E., van Rhijn, Bas W. G., Black, Peter C., and Mertens, Laura S.

Published
2022
Full Text
View/download PDF

26. Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer

Author

Katayama, Satoshi, Schuettfort, Victor M., Pradere, Benjamin, Mori, Keiichiro, Mostafaei, Hadi, Quhal, Fahad, Sari Motlagh, Reza, Laukhtina, Ekaterina, Grossmann, Nico C., Aydh, Abdulmajeed, Rajwa, Pawel, König, Frederik, Karakiewicz, Pierre I., Haydter, Martin, Moschini, Marco, Abufaraj, Mohammad, Lotan, Yair, Lee, Richard K., Trinh, Quoc-Dien, Compérat, Eva, Teoh, Jeremy, Nasu, Yasutomo, and Shariat, Shahrokh F.

Published
2022
Full Text
View/download PDF

29. Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy

Author

Mori, Keiichiro, Schuettfort, Victor M., Katayama, Satoshi, Laukhtina, Ekaterina, Pradere, Benjamin, Quhal, Fahad, Sari Motlagh, Reza, Mostafaei, Hadi, Grossmann, Nico C., Rajwa, Pawel, Teoh, Jeremy YC., Resch, Irene, Fajkovic, Harun, Moschini, Marco, D’andrea, David, Abufaraj, Mohammad, Karakiewicz, Pierre I., Lotan, Yair, Scherr, Douglas, Egawa, Shin, Compérat, Eva, and Shariat, Shahrokh F.

Published
2022
Full Text
View/download PDF

32. The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy

Author

Mori, Keiichiro, Schuettfort, Victor M., Katayama, Satoshi, Laukhtina, Ekaterina, Pradere, Benjamin, Quhal, Fahad, Sari Motlagh, Reza, Mostafaei, Hadi, Grossmann, Nico C., Rajwa, Pawel, König, Frederik, Aydh, Abdulmajeed, Soria, Francesco, Moschini, Marco, Karakiewicz, Pierre I., Lotan, Yair, Scherr, Douglas, Haydter, Martin, Nyirady, Peter, Teoh, Jeremy Y.C., Egawa, Shin, Compérat, Eva, and Shariat, Shahrokh F.

Published
2022
Full Text
View/download PDF

33. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer

Author

Roumiguié, Mathieu, Kamat, Ashish M., Bivalacqua, Trinity J., Lerner, Seth P., Kassouf, Wassim, Böhle, Andreas, Brausi, Maurizio, Buckley, Roger, Persad, Raj, Colombel, Marc, Lamm, Donald, Palou-Redorta, Juan, Soloway, Mark, Brothers, Ken, Steinberg, Gary, Lotan, Yair, Sylvester, Richard, Alfred Witjes, J., and Black, Peter C.

Published
2022
Full Text
View/download PDF

35. ACR Appropriateness Criteria® Pretreatment Staging of Urothelial Cancer: 2024 Update.

Author

Barker, Samantha J., Soylu, Esra, Allen, Brian C., Auron, Moises, Costa, Daniel N., Gerena, Marielia, Lotan, Yair, Rose, Tracy L., Solanki, Abhishek, Surasi, Devaki Shilpa, Turkbey, Baris, Whitworth III, Pat, and Oto, Aytekin

Abstract

Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of imaging for pretreatment staging of urothelial cancer are to evaluate for both local and distant spread of the cancer and assessing for synchronous sites of urothelial cancer in the upper tracts and bladder. For pretreatment staging of urothelial carcinoma, patients can be stratified into one of three groups: 1) nonmuscle invasive bladder cancer; 2) muscle invasive bladder cancer; and 3) upper urinary tract urothelial carcinoma. This document is a review of the current literature for urothelial cancer and resulting recommendations for pretreatment staging imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Interruptions in bladder cancer care during the COVID-19 public health emergency

Author

Gore, John L., Follmer, Kristin, Reynolds, Jason, Nash, Michael, Anderson, Christopher B., Catto, James W.F., Chamie, Karim, Daneshmand, Siamak, Dickstein, Rian, Garg, Tullika, Gilbert, Scott M., Guzzo, Thomas J., Kamat, Ashish M., Kates, Max R., Lane, Brian R., Lotan, Yair, Mansour, Ahmed M., Master, Viraj A., Montgomery, Jeffrey S., Morris, David S., Nepple, Kenneth G., O'Neil, Brock B., Patel, Sanjay, Pohar, Kamal, Porten, Sima P., Riggs, Stephen B., Sankin, Alexander, Scarpato, Kristen R., Shore, Neal D., Steinberg, Gary D., Strope, Seth A., Taylor, Jennifer M., Comstock, Bryan A., Kessler, Larry G., Wolff, Erika M., and Smith, Angela B.

Published
2024
Full Text
View/download PDF

37. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer

Author

Schuettfort, Victor M., Pradere, Benjamin, Trinh, Quoc-Dien, D’Andrea, David, Quhal, Fahad, Mostafaei, Hadi, Laukhtina, Ekaterina, Mori, Keiichiro, Sari Motlagh, Reza, Rink, Michael, Karakiewicz, Pierre I., Chlosta, Piotr, Yuen-Chun Teoh, Jeremy, Lotan, Yair, Scherr, Douglas, Abufaraj, Mohammad, Moschini, Marco, and Shariat, Shahrokh F.

Published
2022
Full Text
View/download PDF

38. Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival

Author

Claps, Francesco, van de Kamp, Maaike W., Mayr, Roman, Bostrom, Peter J., Boormans, Joost L., Eckstein, Markus, Mertens, Laura S., Boevé, Egbert R., Neuzillet, Yann, Burger, Maximilian, Pouessel, Damien, Trombetta, Carlo, Wullich, Bernd, van der Kwast, Theo H., Hartmann, Arndt, Allory, Yves, Lotan, Yair, Shariat, Shahrokh F., Zuiverloon, Tahlita C. M., Mir, M. Carmen, and van Rhijn, Bas W. G.

Published
2021
Full Text
View/download PDF

39. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer

Author

D’Andrea, David, Black, Peter C., Zargar, Homayoun, Zargar-Shoshtari, Kamran, Soria, Francesco, Fairey, Adrian S., Mertens, Laura S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Campain, Nicholas J., Kassouf, Wassim, Dall’Era, Marc A., Seah, Jo-An, Ercole, Cesar E., Horenblas, Simon, Sridhar, Srikala S., McGrath, John S., Aning, Jonathan, Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Grivas, Petros, Stephenson, Andrew J., Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., and Shariat, Shahrokh F.

Published
2021
Full Text
View/download PDF

40. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis

Author

Laukhtina, Ekaterina, Shim, Sung Ryul, Mori, Keiichiro, D‘Andrea, David, Soria, Francesco, Rajwa, Pawel, Mostafaei, Hadi, Compérat, Eva, Cimadamore, Alessia, Moschini, Marco, Teoh, Jeremy Yuen-Chun, Enikeev, Dmitry, Xylinas, Evanguelos, Lotan, Yair, Palou, Juan, Gontero, Paolo, Babjuk, Marko, Witjes, J. Alfred, Kamat, Ashish M., Roupret, Morgan, Shariat, Shahrokh F., and Pradere, Benjamin

Published
2021
Full Text
View/download PDF

41. First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors

Author

Jacob, Joseph M., Woldu, Solomon L., Linehan, Jennifer, Labbate, Craig, Rose, Kyle M., Sexton, Wade J., Tachibana, Isamu, Kaimakliotis, Hristos, Nieder, Alan, Bjurlin, Marc A., Humphreys, Mitchell, Ghodoussipour, Saum B., Quek, Marcus L., Johnson, Brett, O'Donnell, Michael, Eisner, Brian H., Feldman, Adam S., Murray, Katie S., Matin, Surena F., Lotan, Yair, and Dickstein, Rian J.

Published
2024
Full Text
View/download PDF

43. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer

Author

Egloff, Shanna A Arnold, Du, Liping, Loomans, Holli A, Starchenko, Alina, Su, Pei-Fang, Ketova, Tatiana, Knoll, Paul B, Wang, Jifeng, Haddad, Ahmed Q, Fadare, Oluwole, Cates, Justin M, Lotan, Yair, Shyr, Yu, Clark, Peter E, and Zijlstra, Andries

Subjects
Cancer, Urologic Diseases, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Activated-Leukocyte Cell Adhesion Molecule, Aged, Biomarkers, Tumor, Cohort Studies, Computational Biology, Cystectomy, Databases, Genetic, Female, Gene Expression, Gene Expression Profiling, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Proportional Hazards Models, Reproducibility of Results, Urinary Bladder Neoplasms, ALCAM, bladder cancer, transitional cell carcinoma, urothelial cell carcinoma, metastasis, Oncology and Carcinogenesis
Abstract

Proteins involved in tumor cell migration can potentially serve as markers of invasive disease. Activated Leukocyte Cell Adhesion Molecule (ALCAM) promotes adhesion, while shedding of its extracellular domain is associated with migration. We hypothesized that shed ALCAM in biofluids could be predictive of progressive disease. ALCAM expression in tumor (n = 198) and shedding in biofluids (n = 120) were measured in two separate VUMC bladder cancer cystectomy cohorts by immunofluorescence and enzyme-linked immunosorbent assay, respectively. The primary outcome measure was accuracy of predicting 3-year overall survival (OS) with shed ALCAM compared to standard clinical indicators alone, assessed by multivariable Cox regression and concordance-indices. Validation was performed by internal bootstrap, a cohort from a second institution (n = 64), and treatment of missing data with multiple-imputation. While ALCAM mRNA expression was unchanged, histological detection of ALCAM decreased with increasing stage (P = 0.004). Importantly, urine ALCAM was elevated 17.0-fold (P < 0.0001) above non-cancer controls, correlated positively with tumor stage (P = 0.018), was an independent predictor of OS after adjusting for age, tumor stage, lymph-node status, and hematuria (HR, 1.46; 95% CI, 1.03-2.06; P = 0.002), and improved prediction of OS by 3.3% (concordance-index, 78.5% vs. 75.2%). Urine ALCAM remained an independent predictor of OS after accounting for treatment with Bacillus Calmette-Guerin, carcinoma in situ, lymph-node dissection, lymphovascular invasion, urine creatinine, and adjuvant chemotherapy (HR, 1.10; 95% CI, 1.02-1.19; P = 0.011). In conclusion, shed ALCAM may be a novel prognostic biomarker in bladder cancer, although prospective validation studies are warranted. These findings demonstrate that markers reporting on cell motility can act as prognostic indicators.

Published
2017

44. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer.

Author

Arnold Egloff, Shanna A, Du, Liping, Loomans, Holli A, Starchenko, Alina, Su, Pei-Fang, Ketova, Tatiana, Knoll, Paul B, Wang, Jifeng, Haddad, Ahmed Q, Fadare, Oluwole, Cates, Justin M, Lotan, Yair, Shyr, Yu, Clark, Peter E, and Zijlstra, Andries

Subjects
Humans, Activated-Leukocyte Cell Adhesion Molecule, Neoplasm Staging, Prognosis, Cystectomy, Proportional Hazards Models, Cohort Studies, Reproducibility of Results, Gene Expression Profiling, Computational Biology, Gene Expression, Databases, Genetic, Aged, Middle Aged, Female, Male, Urinary Bladder Neoplasms, Biomarkers, Tumor, ALCAM, bladder cancer, metastasis, transitional cell carcinoma, urothelial cell carcinoma, Biomarkers, Tumor, Databases, Genetic, Oncology and Carcinogenesis
Abstract

Proteins involved in tumor cell migration can potentially serve as markers of invasive disease. Activated Leukocyte Cell Adhesion Molecule (ALCAM) promotes adhesion, while shedding of its extracellular domain is associated with migration. We hypothesized that shed ALCAM in biofluids could be predictive of progressive disease. ALCAM expression in tumor (n = 198) and shedding in biofluids (n = 120) were measured in two separate VUMC bladder cancer cystectomy cohorts by immunofluorescence and enzyme-linked immunosorbent assay, respectively. The primary outcome measure was accuracy of predicting 3-year overall survival (OS) with shed ALCAM compared to standard clinical indicators alone, assessed by multivariable Cox regression and concordance-indices. Validation was performed by internal bootstrap, a cohort from a second institution (n = 64), and treatment of missing data with multiple-imputation. While ALCAM mRNA expression was unchanged, histological detection of ALCAM decreased with increasing stage (P = 0.004). Importantly, urine ALCAM was elevated 17.0-fold (P < 0.0001) above non-cancer controls, correlated positively with tumor stage (P = 0.018), was an independent predictor of OS after adjusting for age, tumor stage, lymph-node status, and hematuria (HR, 1.46; 95% CI, 1.03-2.06; P = 0.002), and improved prediction of OS by 3.3% (concordance-index, 78.5% vs. 75.2%). Urine ALCAM remained an independent predictor of OS after accounting for treatment with Bacillus Calmette-Guerin, carcinoma in situ, lymph-node dissection, lymphovascular invasion, urine creatinine, and adjuvant chemotherapy (HR, 1.10; 95% CI, 1.02-1.19; P = 0.011). In conclusion, shed ALCAM may be a novel prognostic biomarker in bladder cancer, although prospective validation studies are warranted. These findings demonstrate that markers reporting on cell motility can act as prognostic indicators.

Published
2017

46. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria

Author

Valenberg, Franciscus Johannes P. van, Hiar, Andrew M., Wallace, Ellen, Bridge, Julia A., Mayne, Donna J., Beqaj, Safedin, Sexton, Wade J., Lotan, Yair, Weizer, Alon Z., Jansz, Godfrey K., Stenzl, Arnulf, Danella, John F., Cline, Kevin J., Williams, Michael B., Montgomery, Scott, David, Richard D., Harris, Richard, Klein, Eric W., Bradford, Timothy J., Wolk, Fred N., Westenfelder, Karl R., Trainer, Andrew F., Richardson, Timothy A., Egerdie, Russell B., Goldfarb, Bernard, Zadra, Joseph A., Lu, Xixi, Simon, Iris M., Campbell, Scott A., Bates, Michael P., Higuchi, Russell G., and Witjes, J. Alfred

Published
2021
Full Text
View/download PDF

47. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma

Author

Kaimakliotis, Hristos Z., Tachibana, Isamu, Woldu, Solomon, Labbate, Craig, Jacob, Joseph, Murray, Katie, Rose, Kyle, Sexton, Wade, Dickstein, Rian, Linehan, Jennifer, Nieder, Alan, Bjurlin, Marc, Humphreys, Mitchell, Ghodoussipour, Saum, Quek, Marcus, O'Donnell, Michael, Eisner, Brian H., Matin, Surena F., Lotan, Yair, and Feldman, Adam S.

Published
2023
Full Text
View/download PDF

49. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial

Author

Gore, John L., du Plessis, Marguerite, Zhang, Jingbin, Dai, Darlene, Thompson, Darby J.S., Karsh, Lawrence, Lane, Brian, Franks, Michael, Chen, David Y.T., Bianco, Fernando J., Jr., Brown, Gordon, Clark, William, Kibel, Adam S., Kim, Hyung, Lowrance, William, Manoharan, Murugesan, Maroni, Paul, Perrapato, Scott, Sieber, Paul, Trabulsi, Edouard J., Waterhouse, Robert, Spratt, Daniel E., Davicioni, Elai, Lotan, Yair, and Lin, Daniel W.

Published
2020
Full Text
View/download PDF

50. Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy

Author

Yeh, Hsin-Chih, Li, Ching-Chia, Chien, Tsu-Ming, Li, Chia-Yang, Cheng, Yen-Chen, Woldu, Solomon L., Robyak, Haley, Huang, Chun-Nung, Ke, Hung-Lung, Li, Wei-Ming, Lee, Hsiang-Ying, Yeh, Bi-Wen, Yang, Sheau-Fang, Tu, Hung-Pin, Sagalowsky, Arthur I., Raman, Jay D., Singla, Nirmish, Margulis, Vitaly, Lotan, Yair, Hsieh, Jer-Tsong, and Wu, Wen-Jeng

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results